Clinical trialObservationalCompleted
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
- Outcome
- Finished, no results posted
- Phase
- Observational
- Status
- Completed
- Study type
- Observational
- Start
- 15 July 2022
- Ended
- 23 March 2026
- Enrollment
- 72 participants
- Sites
- 1
- Primary outcomes
- BOR
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 13 April 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.